AND COGNITIVE IMPAIRMENT
Cognitive disorders involve disturbances in information processing and integration associated with cognitive impairment and/or progressive cognitive decline. These disorders can be studied using translational EEG biomarkers that represent powerful assets to assess procognitive or anti-psychotic treatments efficacy. Our programs feature expertise in developping models of cognitive impairment, validating appropriate methods that seamlessly translate into the clinic (Auditory-evoked potentials, pharmaco-induced models) and skills in analysing complex data sets.
Introducing 40Hz ASSR – Translational Biomarker for Schizophrenia
Want to know more?
Please check out our article on LinkedIn:
Markers: ERPs, EROs, MMN, Gating, Multisite Coherence
Programs: Lead selection (screening of small libraries of compounds), lead validation (dose-response effect, pharmacokinetic), rodent model phenotyping